白介素-13受体IL-13Ralpha2在治疗复发性恶性胶质瘤中的表达降低-INC国际神经外科医生集团

　　白介素-13受体IL-13Ralpha2在治疗复发性恶性胶质瘤中的表达降低（Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas）

　　英文摘要：

　　The IL-13Ralpha2 gene encodes for a 65 kDa protein that forms one of the subunits of the interleukin-13 (IL-13) receptor. This gene is highly expressed in various types of human tumors including malignant gliomas. The expression level of IL-13Ralpha2 was examined in a total of 45 tissue samples of anaplastic astrocytomas (AAs) World Health Organization (WHO) grade III, glioblastomas (GBMs) WHO grade IV, and first-recurrent glioblastomas (frGBMs) after treatment with radiation and chemotherapy. IL-13Ralpha2 expression was detected by semiquantitative reverse transcription real-time polymerase chain reaction (PCR) using ABI PRISM 7700 and Qiagen QuantiTect SYBR Green PCR kits. The expression level of IL-13Ralpha2 (15 fold) was significantly reduced in frGBMs compared to the primary GBMs (p = 0.014), and significantly reduced by more than 15 fold (p = 0.003) in all untreated malignant astrocytomas (AAs and GBMs) compared with treated frGBMs. Expression of IL-13Ralpha2 seems to be lower in frGBMs compared to GBMs. The promising antitumor effect of IL-13 cytotoxin could be greatly reduced in frGBM or only achievable with higher amounts of cytotoxin, due to the significantly lower expression of the cytotoxin's target structure.

　　中文摘要：

　　IL-13Ralpha2基因编码一个65 kDa蛋白，该蛋白形成白细胞介素-13 (IL-13)受体的一个亚基。该基因在包括恶性胶质瘤在内的多种人类肿瘤中均有高表达。检测45例间变性星形细胞瘤(AAs)、间变性星形细胞瘤(GBMs)、间变性星形细胞瘤(GBMs)组织中IL-13Ralpha2的表达水平。半定量逆转录实时聚合酶链反应(PCR)检测IL-13Ralpha2表达，ABI PRISM 7700和Qiagen定量SYBR Green PCR试剂盒检测。IL-13Ralpha2的表达水平(15倍)在frGBMs中较初级GBMs降低(p = 0.014)，在全部未经治疗的恶性星形细胞瘤(AAs和GBMs)中较经治疗的恶性星形细胞瘤(frGBMs)降低15倍以上(p = 0.003)。与GBMs相比，frGBMs中IL-13Ralpha2的表达似乎更低。IL-13细胞毒素的抗肿瘤作用在frGBM中可能大大降低，或者只有在细胞毒素含量较高的情况下才能达到，因为细胞毒素的靶结构表达明显降低。

复发性恶性胶质瘤

　　该论文主要研究人员之一为INC国际神经外科医生集团旗下组织国际神经外科顾问团(WANG)成员，德国汉诺威国际神经科学研究所(INI)神经外科教授和血管神经外科主任巴特朗菲教授。巴特朗菲教授擅长大脑半球病变、脑干病变、脑血管疾病、脑内深层区胶质瘤、颅颈交界处的病变等的肿瘤切除术、神经吻合术以及各种椎管内肿瘤切除术，以高超的技术手法和顺利前提下高切除率手术而，在中国患者群中被尊称为“巴教授”。每年的手术量在400台以上，且是高难度手术。

　　巴特朗菲教授作为INC国际神经外科医生集团旗下组织国际神经外科顾问团(WANG)中的一员，曾受邀来华参与了多场国内高要求的神经外科学术会议，与国内众多神经外科专家共同聚首探讨当前前沿的神经外科咨询理念、方法和技术，较大促进了中外神经外科事业的交流与发展。